Barrett Bready is the Founder and CEO of Nabsys. He was founding CEO of Nabsys in 2005, helped lead development of the core technologies, and raised $80 million in venture financing to support the company’s early growth. His technical and business leadership has resulted in the successful development and commercialization of HD-Mapping™, electronic high-definition whole-genome mapping.
Dr. Bready is an adjunct professor at Brown University where he lectures on the rapidly evolving business of biotechnology. He serves as a commissioner of the I-195 Redevelopment District Commission, a major land redevelopment initiative in downtown Providence, RI with a focus on life sciences and other high-technology sectors. He has received numerous awards including, in 2011, Rhode Island Innovator of the Year, and in 2018, a career achievement award from the Warren Alpert Medical School of Brown University. Dr. Bready received an M.D. and an Sc.B. in physics from Brown University, both as part of Brown’s Program in Liberal Medical Education (PLME).
John Oliver, Ph.D.
Chief Technology Officer
John Oliver has directed the research efforts at Nabsys since he joined the company in March 2007. Dr. Oliver brings over 25 years of research expertise to Nabsys. His diverse experience includes synthetic organic chemistry, biochemistry, molecular biology, surface chemistry, and microarray technology. his technical leadership has been instrumental in the development of high-definition electronic whole-genome mapping. Prior to joining Nabsys, Dr. Oliver was Chief Scientific Officer and Co-Founder at GeneSpectrum, a biotechnology company developing patterned probes for application to sequencing by hybridization. Dr. Oliver was Assistant Professor of Chemistry at Brown University. He received his Ph.D. in chemistry from Northwestern University and his B.S. in chemistry from Harvey Mudd College.
Executive Vice President of Product Development
Steve Nurnberg is responsible for leading product development at Nabsys. He is a 35-year veteran of life science instrumentation and consumables. Mr. Nurnberg has an extensive track record of innovation and commercialization of products that have changed the way scientists and engineers solve problems, most recently using micro and nanofluidics He has held technical and senior management positions in startups to large public companies including Corning Medical, Waters, Millipore, PerSeptive Biosystems, Perkin Elmer, Applied Biosystems and IDEX Health & Science. He has a B.S. in Electrical Engineering from Cornell University.
Vice President of Software & Informatics
Michael Kaiser joined Nabsys in 2012 and is responsible for leading the Company’s software and informatics development efforts. He is a strong technical leader with a proven track record of developing and applying the technologies critical for creating break-through products. He has held technical and management positions in life science companies, for 30 years. His hardware and software IP are key components in novel instrumentation developed by Affymetrix and Covaris. Mr. Kaiser received his a B.S. in Electrical Engineering from the University of Rochester.
Chief Commercial Officer
Justin is responsible for the commercialization of Nabsys’ HD-Mapping™. He was previously part of CENTOGENE GmbH Executive Leadership Team as the Senior Vice President of Business Development where he managed the company’s commercial business. Prior to CENTOGENE, Justin was the Head of Business Development at Synthetic Genomics, Inc. a synthetic biology company responsible for the launch and commercialization of the first bench top DNA assembly system. Justin has held scientific roles at both the Genomics Institute of the Novartis Research Foundation (GNF) and the Exploratory Technologies Department at Pfizer, Inc. Justin received a B.A. in molecular, cellular, developmental biology from the University of California, Santa Cruz and an M.B.A. from the Rady School of Business at the University of California, San Diego.
Nabsys develops semiconductor-based tools for genomic analysis that are capable of analyzing entire genomes in very large fragments.